£112.65

It has never been this cheap. We have no record of a lower price.

£113 today · cheaper than every other day in the last 3 months

Horizons in Cancer Research. Volume 73: Volume 73

View at Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 21 days · 21 data points (no recent data)

Historical
Generating forecast…
£113.87 £112.53 £112.82 £113.11 £113.41 £113.70 £113.99 26 July 2026 31 July 2026 05 August 2026 10 August 2026 15 August 2026
View at Amazon ↗

Price data last checked 70 day(s) ago - refreshing...

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 21 days • 2 price levels

Days at Price
Current Price
6 days · current 15 days 0 4 8 11 15 £113 £114 Days at Price

Price Analysis

Most common price: £114 (15 days, 71.4%)

Price range: £113 - £114

Price levels: 2 different prices over 21 days

Description

In Horizons in Cancer Research. Volume 73, after the identification of some small subgroups with a strong biological-molecular identity, the current evidence regarding the prognostic factors of patients with non-eradicable metastatic disease are examined. The goal is to discuss disease subgroups, which may sometimes provide conditions for decisions that are less compliant with current clinical practice and help define new stratification criteria for patients enrolled in prospective studies. Following this, the authors summarize the current knowledge on breast cancer with an introduction on the traditional markers used in the diagnosis of this disease, followed by an account of the emerging markers. Next, the underlying mechanisms of DNA replication, damage and repair are discussed. Further, RAD51 is proposed as a potential means of managing chemoresistant cancers. Certain drugs and strategies can sensitize chemotherapy via impacting on RAD51, which can be developed as chemotherapy modulators. The authors also discuss multiple myeloma, an incurable malignant tumor of plasma cells of the bone marrow, which is the most common primary neoplasm arising in bone. It causes approximately 1% of cancer-related deaths and is the 2nd most common hematological malignancy in the western world. Later, this collection discusses the prevalence and types of infectious complications that patients with multiple myeloma face, as well as present and emerging therapeutic approaches. The concluding study indicates proteins that have a promising future as new anticancer drugs, in conjunction with the in vitro and/or in vivo effects of these bioactive proteins derived from plants.

Product Specifications

Format
hardcover
Domain
Amazon UK
Release Date
15 October 2019
Listed Since
18 July 2019

Barcode

No barcode data available

Similar Products You Might Like

Multiple Myeloma: 183 (Recent Results in Cancer Research, 183)
97% match

Multiple Myeloma: 183 (Recent Results in Cancer Research, 183)

Springer

£103.09 12 Aug 2026
Advances in Biology and Therapy of Multiple Myeloma Volume 2
97% match

Advances in Biology and Therapy of Multiple Myeloma Volume 2

Springer

£111.90 13 Oct 2026
Multiple Myeloma and Related Disorders (Hodder Arnold Publication)
97% match

Multiple Myeloma and Related Disorders (Hodder Arnold Publication)

CRC Press

£148.94 14 Aug 2026
Multiple Myeloma: Risk Factors, Diagnosis & Treatments (Cancer Etiology, Diagnosis and Treatments)
97% match

Multiple Myeloma: Risk Factors, Diagnosis & Treatments (Cancer Etiology, Diagnosis and Treatments)

£130.52 15 Aug 2026
Treatment of Multiple Myeloma and Related Disorders
97% match

Treatment of Multiple Myeloma and Related Disorders

Cambridge University Press

£36.41 17 Sep 2026
Multiple Myeloma: Symptoms, Diagnosis and Treatment (Cancer Etiology, Diagnosis and Treatments Series)
97% match

Multiple Myeloma: Symptoms, Diagnosis and Treatment (Cancer Etiology, Diagnosis and Treatments Series)

£92.80 25 Sep 2026
Contemporary Management of Multiple Myeloma
96% match

Contemporary Management of Multiple Myeloma

Jaypee Brothers Medical Publishers

£39.79 22 Sep 2026
Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside
96% match

Bone Cancer: Bone Sarcomas and Bone Metastases - From Bench to Bedside

Elsevier

£167.99 22 Aug 2026
Multiple Myeloma and Other Plasma Cell Neoplasms: 0 (Hematologic Malignancies)
96% match

Multiple Myeloma and Other Plasma Cell Neoplasms: 0 (Hematologic Malignancies)

Springer

£99.39 11 Sep 2026
Multiple Myeloma: Methods and Protocols: 113 (Methods in Molecular Medicine, 113)
96% match

Multiple Myeloma: Methods and Protocols: 113 (Methods in Molecular Medicine, 113)

Humana

£61.58 23 Sep 2026
Multiple Myeloma: 183 (Recent Results in Cancer Research, 183)
96% match

Multiple Myeloma: 183 (Recent Results in Cancer Research, 183)

Springer

£80.67 24 Sep 2026
Recent Updates on Multiple Myeloma
96% match

Recent Updates on Multiple Myeloma

IntechOpen

£119.00 24 Sep 2026
Multiple Myeloma & Plasma Cell Neoplasms Clinical Guide
96% match

Multiple Myeloma & Plasma Cell Neoplasms Clinical Guide

Springer

£111.67 08 Oct 2026
Epidemiology and Biology of Multiple Myeloma
96% match

Epidemiology and Biology of Multiple Myeloma

Springer

£77.90 23 Sep 2026
Hematologic Malignancies: Multiple Myeloma and Related Plasma Cell Disorders
96% match

Hematologic Malignancies: Multiple Myeloma and Related Plasma Cell Disorders

Springer

£140.60 14 Aug 2026
Bortezomib in the Treatment of Multiple Myeloma (Milestones in Drug Therapy)
96% match

Bortezomib in the Treatment of Multiple Myeloma (Milestones in Drug Therapy)

Springer

£83.26 09 Oct 2026
Multiple Myeloma: Methods and Protocols: 1792 (Methods in Molecular Biology, 1792)
96% match

Multiple Myeloma: Methods and Protocols: 1792 (Methods in Molecular Biology, 1792)

Humana

£73.48 13 Oct 2026
Biology and Management of Multiple Myeloma (Current Clinical Oncology)
96% match

Biology and Management of Multiple Myeloma (Current Clinical Oncology)

Humana

£69.13 24 Sep 2026
Multiple Myeloma: Methods and Protocols: 1792 (Methods in Molecular Biology, 1792)
96% match

Multiple Myeloma: Methods and Protocols: 1792 (Methods in Molecular Biology, 1792)

Humana

£103.27 13 Aug 2026
Biology and Management of Multiple Myeloma (Current Clinical Oncology)
96% match

Biology and Management of Multiple Myeloma (Current Clinical Oncology)

Humana

£113.76 03 Oct 2026
Resistance to Targeted Therapies in Multiple Myeloma: 22 (Resistance to Targeted Anti-Cancer Therapeutics, 22)
96% match

Resistance to Targeted Therapies in Multiple Myeloma: 22 (Resistance to Targeted Anti-Cancer Therapeutics, 22)

Springer

£100.11 12 Sep 2026
Resistance to Targeted Therapies in Multiple Myeloma: 22 (Resistance to Targeted Anti-Cancer Therapeutics, 22)
96% match

Resistance to Targeted Therapies in Multiple Myeloma: 22 (Resistance to Targeted Anti-Cancer Therapeutics, 22)

Springer

£100.11 04 Oct 2026
Genetic and Molecular Epidemiology of Multiple Myeloma
96% match

Genetic and Molecular Epidemiology of Multiple Myeloma

Springer

£79.69 08 Sep 2026
Myeloma Bone Disease (Current Clinical Oncology)
95% match

Myeloma Bone Disease (Current Clinical Oncology)

Humana

£155.63 15 Aug 2026